ArticleBrain and behavior2021
Antiseizure medications for post-stroke epilepsy: A real-world prospective cohort study.
Article in Brain and behavior, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antiseizure Medications in Poststroke Seizures: A Systematic Review and Network Meta-Analysis.Neurology · 2025Pooled it
- Outcomes of patients with post-stroke epilepsy: A scoping review on quality of life, readmissions, costs, seizure recurrence, and medication adherence.Epilepsia open · 2026Review
- Nonlinear Association Between the C-Reactive Protein-To-Albumin Ratio and Post-Stroke Epilepsy Risk.CNS neuroscience & therapeutics · 2026Article
- Status epilepticus of carotid web after carotid artery stenting: A case report.The Journal of international medical research · 2025Article
- Review
- Differences in patterns of outpatient epilepsy-specific medication initiation after acute ischemic stroke in the Medicare population.Epilepsia · 2025Observational
- Comparative risk of major health events among individuals prescribed different antiseizure medications following ischemic stroke.Epilepsia · 2025Article
- Pharmacological strategies for preventing post-stroke seizures and epilepsy.Frontiers in neurology · 2025Review
- Pathophysiology, Diagnosis, Prognosis, and Prevention of Poststroke Epilepsy: Clinical and Research Implications.Neurology · 2024Review
- Efficacy and safety of Perampanel in the treatment of post stroke epilepsy: A multicenter, real-world study.Heliyon · 2024Article
- Stroke-related epilepsy in the rehabilitation setting: Insights from the inpatient post-stroke rehabilitation study - RIPS.Epilepsy & behavior reports · 2024Article
- Using spectral and temporal filters with EEG signal to predict the temporal lobe epilepsy outcome after antiseizure medication via machine learning.Scientific reports · 2023Article
- Shift from older- to newer-generation antiseizure medications in people with acute ischemic stroke in Australia: A population-based study.Epilepsia open · 2023Article
- Observational
- Association of Cortical Superficial Siderosis with Post-Stroke Epilepsy.Annals of neurology · 2023Article
- Developing an Asymmetry Method for Detecting Postictal Hyperperfusion in Poststroke Epilepsy.Frontiers in neurology · 2022Article
- Interictal epileptiform discharges as a predictive biomarker for recurrence of poststroke epilepsy.Brain communications · 2022Article
- Poststroke Seizure and Epilepsy: A Review of Incidence, Risk Factors, Diagnosis, Pathophysiology, and Pharmacological Therapies.Oxidative medicine and cellular longevity · 2022Review
- Antiseizure medications for post-stroke epilepsy: A real-world prospective cohort study.Brain and behavior · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThe management of post-stroke epilepsy (PSE) should ideally include prevention of both seizure and adverse effects; however, an optimal antiseizure medications (ASM) regimen has yet been established. The purpose of this study is to assess seizure recurrence, retention, and tolerability of older-generation and newer-generation ASM for PSE.
methodsThis prospective multicenter cohort study (PROgnosis of Post-Stroke Epilepsy [PROPOSE] study) was conducted from November 2014 to September 2019 at eight hospitals. A total of 372 patients admitted and treated with ASM at discharge were recruited. Due to the non-interventional nature of the study, ASM regimen was not adjusted and followed standard hospital practices. The primary outcome was seizure recurrence in patients receiving older-generation and newer-generation ASM. The secondary outcomes were the retention and tolerability of ASM regimens.
resultsOf the 372 PSE patients with ASM at discharge (median [IQR] age, 73 [64-81] years; 139 women [37.4%]), 36 were treated with older-generation, 286 with newer-generation, and 50 with mixed-generation ASM. In older- and newer-generation ASM groups (n = 322), 98 patients (30.4%) had recurrent seizures and 91 patients (28.3%) switched ASM regimen during the follow-up (371 [347-420] days). Seizure recurrence was lower in newer-generation, compared with the older-generation, ASM (hazard ratio [HR], 0.42, 95%CI 0.27-0.70; p = .0013). ASM regimen withdrawal and change of dosages were lower in newer-generation ASM (HR, 0.34, 95% CI 0.21-0.56, p < .0001).
conclusionsNewer-generation ASM possess advantages over older-generation ASM for secondary prophylaxis of post-stroke seizures in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.